Aldagen Files andIPO Despite Tough Market

On the same day that Elixir Pharmaceuticals canned its IPO plans citing tough market conditions, Aldagen filed an S-1 expecting to raise as much as $81M.  The company has not yet issued details of how many shares they expect to offer or even the share price. The only biotech, US IPO was Bioheart Inc.’s infinitesimal [...]